UBS Group
CTNM

UBS Group’s Contineum Therapeutics CTNM Stock Holding History

UBS Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.01M Buy
230,409
+31,020
+16% +$416K ﹤0.01% 4589
2025
Q4 		$2.28M Buy
199,389
+130,885
+191% +$1.49M ﹤0.01% 4853
2025
Q3 		$805K Buy
68,504
+60,839
+794% +$490K ﹤0.01% 5733
2025
Q2 		$30.4K Sell
7,665
-5,629
-42% -$24.5K ﹤0.01% 8149
2025
Q1 		$92.8K Sell
13,294
-11,587
-47% -$105K ﹤0.01% 7098
2024
Q4 		$365K Buy
24,881
+22,221
+835% +$352K ﹤0.01% 6062
2024
Q3 		$50.9K Buy
2,660
+553
+26% +$10.6K ﹤0.01% 6810
2024
Q2 		$37.1K Buy
+2,107
New +$33.9K ﹤0.01% 6916

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's CTNM Position: Q1 2026 in Review

UBS Group increased its Contineum Therapeutics (CTNM) stake by 16% in Q1 2026, buying an estimated $416K and bringing the position to 230,409 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4589.

UBS Group first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • UBS Group held 230,409 shares of Contineum Therapeutics worth $3.01M as of Q1 2026.
  • UBS Group bought 31,020 Contineum Therapeutics shares in Q1 2026, an estimated $416K.
  • Contineum Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4589 holding.
  • UBS Group first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.